Great Lakes Clinical Trials Doses First Patient in a Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

December 7, 2021
Chicago, IL

Great Lakes Clinical Trials, a leading community-based research center located in Chicago, announced that their first participant has been dosed in the Phase 2 randomized, double-blind study of single dose psilocybin vs placebo.  The purpose of this research is to study the medical and safety effects of a single dose of psilocybin compared to a placebo in participants with MDD.  Each participant is randomized to receive either a one-time dose of psilocybin or a placebo.

Psilocybin is a natural product produced by numerous species of mushrooms, that falls into a pharmacological class referred to as “classic psychedelics.” The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.

“I am honored that our organization is participating on this important clinical trial,” says Steve Satek, President and Founder of Great Lakes Clinical Trials.  “Depression effects millions of Americans and the prospect of a psychedelic drug like psilocybin as potential new therapy is exciting.”

“It’s an important mission of Great Lakes Clinical Trials to bring access to these types of clinical trials to our local community on the north side of Chicago, a community which otherwise has limited access to these types of new, innovative therapeutics,” Satek adds.

Great Lakes Clinical trials is one of nine research centers around the country participating in this Phase 2 clinical trial, sponsored by Usona Institute.  For more information about this trial or to be considered for participation, please visit Usona Institute’s website by clicking here or Great Lakes Clinical Trials website by clicking here.

About Great Lakes Clinical Trials

Great Lakes Clinical Trials is an independent, phase I-IV clinical trials center, with 5 locations throughout the Chicago region, specializing in the study of investigational medications, food products, devices and supplements for the treatment of chronic diseases, notably in mental health, memory disorders, COVID-19, rheumatology, vaccines, and nutrition.  All medical services at Great Lakes Clinical Trials are provided free-of-charge, and are led by board-certified physicians.  For more information, please visit our website at www.greatlakesclinicaltrials.com

About Usona Institute

Please visit the Usona Institute website at www.usonainstitute.org.